To better understand tissue and genomic determinants underlying sensitivity to multivalent TRAIL-R2 agonists across the spectrum of cancer types, we next assessed response to MEDI3039 across a panel of 758 well-characterized cancer cell lines representing 19 tissue types (Supplementary Fig. S2B; Supplementary Table S9; ref. 9). This evidence concerns the gene TNFRSF10B and cancer.